ŗ£½ĒĘĘ½ā°ę

  • Compare Products
Menu
Account
Stay informed about relevant trends, useful soft skills, and important efforts from within the scientific community. Explore Lab Coats & Lifeā„¢ resources.    Browse Resources >

CellPoreā„¢ FITC-Dextran

Fluorescent tracer for visualizing and optimizing intracellular delivery efficiency with CellPoreā„¢ Transfection System

Loading...
 
 
For cartridge selection and optimized operating parameters, refer to the .

CellPoreā„¢ FITC-Dextran

Fluorescent tracer for visualizing and optimizing intracellular delivery efficiency with CellPoreā„¢ Transfection System

Catalog #
(Select a product)
Fluorescent tracer for visualizing and optimizing intracellular delivery efficiency with CellPoreā„¢ Transfection System
Request Pricing Request Pricing

Product Advantages

  • Optimize mechanoporation efficiency with a ready-to-use positive control cargo 
  • Quantify intracellular delivery by flow cytometry to optimize pressure while maintaining cell viability
  • Maintain cell health and data quality with minimal toxicity and low immunogenicity
  • Co-deliver with functional cargo and use in multicolor panels to monitor delivery efficiency in complex assays
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.
  1. CellPore™ Transfection System
    CellPoreā„¢ Transfection System

    Cell mechanoporation system for transfection & intracellular delivery

  2. CellPore™ Delivery Cartridges
    CellPoreā„¢ Delivery Cartridges

    Single-use mechanoporation cartridges for the CellPoreā„¢ Transfection System, enabling efficient intracellular delivery into immune cells, HSPCs, and hPSCs

  3. CellPore™ Delivery Media
    CellPoreā„¢ Delivery Media

    Delivery media specially designed to achieve optimal transfection efficiency and high viability of immune cells, HSPCs, and hPSCs when used with the CellPoreā„¢ Transfection System

Overview

Optimize mechanoporation-based delivery with the CellPoreā„¢ Transfection System by using CellPoreā„¢ FITC-Dextran, a green fluorescent tracer designed to assess transfection efficiency. CellPoreā„¢ FITC-Dextran comes in a ready-to-use format, making it an easy-to-use universal positive control cargo for all your applications.

This hydrophilic polysaccharide, consisting of dextran labeled with fluorescein isothiocyanate (FITC), is characterized by minimal toxicity and low immunogenicity, enabling reliable downstream analysis with minimal impact on cell health.

During mechanoporation, transient membrane permeabilization enables rapid FITC-dextran entry, resulting in markedly stronger intracellular fluorescence compared to natural uptake by endocytosis. Use CellPoreā„¢ FITC-Dextran as a positive control to determine the optimal CellPoreā„¢ delivery pressure for your cell type and application. Following your initial optimization run, select the pressure that maximizes uptake while preserving viability for subsequent experiments. CellPoreā„¢ FITC-Dextran can also be co-delivered with other functional cargo to track transfection efficiency in parallel with functional assays. Delivery performance can be analyzed by flow cytometry, and the marker is compatible with multi-color staining panels.

For best results, use in conjunction with the CellPoreā„¢ Transfection System, CellPoreā„¢ Delivery Cartridges, and CellPoreā„¢ Delivery Media.

For more information about CellPoreā„¢, including the intracellular delivery technology used in the CellPoreā„¢ Transfection System, visit the CellPoreā„¢ overview page.
Cell Type
Hematopoietic Stem and Progenitor Cells, Monocytes, NK Cells, Pluripotent Stem Cells, T Cells, T Cells, CD4+, T Cells, CD8+
Species
Human, Mouse
Application
Genome Editing
Brand
CellPore
Area of Interest
Disease Modeling, Immunology

Data Figures

Rapid Identification of Optimal Delivery Pressures for Distinct T Cell Subsets Using CellPoreā„¢ FITC-Dextran

Figure 1. Rapid Identification of Optimal Delivery Pressures for Distinct T Cell Subsets Using CellPoreā„¢ FITC-Dextran

Pan T cells, CD4+ T cells, CD8+ T cells, and Regulatory T cells (Tregs) were isolated and subjected to a pressure sweep using FITC-Dextran to determine optimal delivery conditions for each subtype. Delivery was performed using CellPoreā„¢ Delivery Cartridge 300 and Delivery Medium A for all subtypes. The optimal delivery pressure ranges were (A) 70 - 90 psi for pan T cells, (B) 50 - 70 psi for CD4+ T cells, (C) 60 - 70 psi for CD8+ T cells, and (D) 50 - 70 psi for Tregs. All conditions were assessed by flow cytometry on the same day of delivery. The endocytosis control represents the natural uptake of CellPoreā„¢ FITC-Dextran in undelivered samples. Untreated refers to unmanipulated cells. These profiles serve as the predictive foundation for delivering biological cargoes to these subtypes. Data are shown as mean Ā± SD (n = 3 - 5).

Optimization with CellPoreā„¢ FITC-Dextran Accurately Predicts mRNA Delivery and Expression Efficiency in Human NK Cells

Figure 2. Optimization with CellPoreā„¢ FITC-Dextran Accurately Predicts mRNA Delivery and Expression Efficiency in Human NK Cells

(A) FITC-dextran was delivered to 2 x 106 human NK cells using CellPoreā„¢ Delivery Cartridge 300 and Delivery Medium A across increasing pressure segments (30 to 90 psi). Delivery efficiency and viability was assessed by flow cytometry on the same day of the experiment and optimal performance was obtained at 70 psi (delivery 93 Ā± 3%; viability 85 Ā± 4%). To validate the predictive power of FITC-Dextran, both (B) eGFP and (C) mCherry mRNA were delivered to 2 x 106 human NK cells from the same donors. The high expression (> 90%) and viability (> 80%) obtained with the mRNA cargoes after 24 hours correlated directly with the optimization parameters established by the FITC-dextran screen. Data are shown as mean Ā± SD; n = 2 - 3.

CellPoreā„¢ FITC-Dextran Serves As a Predictive Surrogate for Cas9 RNP-Mediated Gene Editing in CD34+ Hematopoietic Stem and Progenitor Cells

Figure 3. CellPoreā„¢ FITC-Dextran Serves As a Predictive Surrogate for Cas9 RNP-Mediated Gene Editing in CD34+ Hematopoietic Stem and Progenitor Cells

(A) FITC-dextran was delivered to 5 x 104 cord blood CD34+ hematopoietic stem and progenitor cells (HSPCs) using CellPoreā„¢ Delivery Cartridge 300 and Delivery Medium A across increasing pressure segments (10 to 50 psi) to rapidly identify the pressure balancing delivery efficiency and viability. Flow cytometry analysis on the day of the experiment identified 30 psi as the optimal condition. (B) Functional validation was subsequently performed using Cas9 ribonucleoprotein (RNP) targeting the B2M gene across a similar pressure range. The maximal MHC-I knockout efficiency measured at Day 4 correlated precisely with the 30 psi condition identified before, confirming the utility of CellPoreā„¢ FITC-Dextran for optimizing gene editing workflows. ā€œNon-Targetingā€ represents delivery of non-targeting RNP complexes. Data are presented as mean Ā± SD; n = 3 - 6.

Rapid Screening of Delivery Parameters for Human Pluripotent Stem Cells Using CellPoreā„¢ FITC-Dextran

Figure 4. Rapid Screening of Delivery Parameters for Human Pluripotent Stem Cells Using CellPoreā„¢ FITC-Dextran

Newly passaged hPSC lines were cultured in complete mTeSRā„¢ Medium for 7 days or until reaching 70% confluency. FITC-dextran was delivered to 3.5 x 105 hPSCs using CellPoreā„¢ Delivery Cartridge 500 and Delivery Medium B across increasing low pressure segments (5 to 25 psi). Immediate analysis allowed for the quick identification of 15 psi as the optimal condition across three different lines: (A) SCTi003-A iPSC, (B) WLS-1C iPSC, and (C) H9 ESC line. This highlights the utility of the surrogate cargo for establishing safe, effective delivery parameters for sensitive cell types prior to introducing valuable biological cargoes. Data are presented as mean Ā± SD (n = 3).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
100-1024
Lot #
All
Language
English
Document Type
Product Name
Catalog #
100-1024
Lot #
All
Language
English

Applications

Resources and Publications

Educational Materials (14)

Brochure
Brochure
Brochure
Gene Editing Human Unactivated T Cells with the CellPoreā„¢ Transfection System
Protocol
Gene Editing Human Unactivated T Cells with the CellPoreā„¢ Transfection System
Gene Editing Human Pluripotent Stem Cells (hPSCs) Using the CellPoreā„¢ Transfection System
Protocol
Gene Editing Human Pluripotent Stem Cells (hPSCs) Using the CellPoreā„¢ Transfection System
Gene Editing Human Peripheral Blood Natural Killer Cells Using the CellPoreā„¢ Transfection System
Protocol
Gene Editing Human Peripheral Blood Natural Killer Cells Using the CellPoreā„¢ Transfection System
Gene Editing Human CD34+ Hematopoietic Stem and Progenitor Cells with the CellPoreā„¢ Transfection System
Protocol
Gene Editing Human CD34+ Hematopoietic Stem and Progenitor Cells with the CellPoreā„¢ Transfection S...
CellPoreā„¢: For Gentle Intracellular Delivery
1:54
Video
CellPoreā„¢: For Gentle Intracellular Delivery
How to Use the CellPoreā„¢ Transfection System
8:00
Video
How to Use the CellPoreā„¢ Transfection System
Transform Intracellular Delivery Using the CellPoreā„¢ Transfection System
32:51
Webinar
Transform Intracellular Delivery Using the CellPoreā„¢ Transfection System
Scientific Poster
Scientific Poster
Scientific Poster
Scientific Poster
For cartridge selection and optimized operating parameters, refer to the .
Legal Statement:

The purchase of a CellPoreā„¢ Transfection System, CellPoreā„¢ Delivery Cartridges, and associated reagents (ā€œCellPoreā„¢ Productsā€) conveys to the purchaser a limited, non-exclusive, non-transferable license to use CellPoreā„¢ Products, in accordance with ŗ£½ĒĘĘ½ā°ę's Terms and Conditions of Sale and all applicable laws and regulations, and solely for research-use-only applications (which applications exclude any commercial application or any therapeutic, prophylactic, diagnostic application, as well as any development and/or commercialization of products therewith or developed therefrom). CellPoreā„¢, SQZā„¢, Cell Squeezeā„¢, and Empower Cells to Change Livesā„¢ are trademarks of ŗ£½ĒĘĘ½ā°ę Technologies Canada Inc., following its acquisition of SQZ Biotech. Nothing in this agreement grants the purchaser any rights to use these trademarks without prior written permission from ŗ£½ĒĘĘ½ā°ę. ŗ£½ĒĘĘ½ā°ę or its licensor(s) grant no additional license rights other than those explicitly granted herein, and except for such limited license rights, all other intellectual property and proprietary rights in and to CellPoreā„¢ Products are and shall remain the exclusive property of ŗ£½ĒĘĘ½ā°ę and its licensors. The purchaser of CellPoreā„¢ Products agrees to prevent unauthorized use, access, copying, or disclosure of any intellectual property comprised in CellPoreā„¢ Products. The purchaser shall not, and shall not permit anyone to, copy, create any derivative work, reverse engineer, disassemble, decompile, or make improvements to CellPoreā„¢ products. Users and purchasers of CellPoreā„¢ products hereby grant to ŗ£½ĒĘĘ½ā°ę exclusive ownership and all rights, title, and interest in and to any improvements made, by purchasers or users, to the CellPoreā„¢ products (including any improvements by purchasers or users to the intellectual property directly related to CellPoreā„¢ products), provided however that the user or purchaser who makes the improvement retains a limited, non-transferable license to use such improvement for its internal, non-commercial research use, in accordance with this agreement, only so long as such user or purchaser is in compliance with this agreement. All data, information, and results (to the extent they do not constitute improvements of CellPoreā„¢ products) entered, stored, compiled, generated, and/or analyzed by purchasers of CellPoreā„¢ products using the CellPoreā„¢ products in accordance with all of the foregoing shall be the property of such purchaser. CellPoreā„¢ Transfection System and CellPoreā„¢ Delivery Cartridges (ā€œCellPoreā„¢ Productsā€) are protected by patents in the U.S. and elsewhere. More information can be found at www.cellpore.com. The list of products and patents contained therein are subject to change as a result of routine prosecution and dependent on the patent life cycle as determined by the laws of each jurisdiction in which a relevant patent is in effect.



Quality Statement:

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT ŗ£½ĒĘĘ½ā°ę, REFER TO WWW.ŗ£½ĒĘĘ½ā°ę.COM/COMPLIANCE.

Copyright Ā© 2026 ŗ£½ĒĘĘ½ā°ę. All rights reserved.